Cusini M, Salmaso F, Zerboni R, Carminati G, Vernaci C, Franchi C, Locatelli A, Alessi E
Centro Malattie a Trasmissione Sessuale, Istituto di Scienze Dermatologiche, IRCCS Ospedale Maggiore Milano, Via Pace 9, 20122 Milan, Italy.
Int J STD AIDS. 2004 Jan;15(1):17-20. doi: 10.1258/095646204322637191.
The efficacy of imiquimod in the treatment of external genital warts in HIV positive subjects was compared to a group of patients with normal immune function. Imiquimod 5% cream was applied by patients three times a week until resolution for a maximum of 16 weeks. Assessment for response and the occurrence of side effects was performed every four weeks. Thirty-one per cent of 75 HIV positive patients achieved a complete clearance, a partial response was obtained in 24% of subjects while in 45% we observed no clinical response. In the control group a total clearance was obtained in 62% of subjects, a partial response in 24% and no response in 14%. Recurrences occurred in 4/23 HIV patients and 2/31 immunocompetent patients within three months of follow-up. Side effects were minor to moderate. We conclude that imiquimod 5% cream has an acceptable efficacy and safety on HIV patients.
将咪喹莫特治疗HIV阳性患者外生殖器疣的疗效与一组免疫功能正常的患者进行了比较。5%咪喹莫特乳膏由患者每周涂抹三次，直至疣体消退，最长使用16周。每四周进行一次反应评估和副作用发生情况评估。75例HIV阳性患者中，31%实现了完全清除，24%的患者有部分反应，而45%的患者未观察到临床反应。在对照组中，62%的患者实现了完全清除，24%有部分反应，14%无反应。在随访的三个月内，4/23例HIV患者和2/31例免疫功能正常的患者出现了复发。副作用为轻至中度。我们得出结论，5%咪喹莫特乳膏对HIV患者具有可接受的疗效和安全性。
